WEKO3
アイテム
{"_buckets": {"deposit": "1477925c-d6fa-4811-86ac-4b7c13058006"}, "_deposit": {"created_by": 2, "id": "9845", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "9845"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00009845", "sets": ["9"]}, "author_link": ["39825", "39834", "39836", "39826", "39830", "39835", "39829", "39832", "39827", "39833", "39831", "39828"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-09-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "3106", "bibliographicPageStart": "3097", "bibliographicVolumeNumber": "97", "bibliographic_titles": [{"bibliographic_title": "The Journal of clinical endocrinology \u0026 metabolism"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Context: Weekly teriparatide injection at a dose of 56.5 μg has been shown to increase bone mineral density. Objective: A phase 3 study was conducted to determine the efficacy of once-weekly teriparatide injection for reducing the incidence of vertebral fractures in patients with osteoporosis. Design and Setting: In this randomized, multicenter, double-blind, placebo-controlled trial conducted in Japan, the incidence of morphological vertebral fractures by radiographs was assessed. Patients: Subjects were 578 Japanese patients between the ages of 65 and 95 yr who had prevalent vertebral fracture. Intervention: Subjects were randomly assigned to receive once-weekly sc injections of teriparatide (56.5 μg) or placebo for 72 wk. Main Outcome Measure: The primary endpoint was the incidence of new vertebral fracture. Results: Once-weekly injections of teriparatide reduced the risk of new vertebral fracture with a cumulative incidence of 3.1% in the teriparatide group, compared with 14.5% in the placebo group (P \u003c 0.01), and a relative risk of 0.20 (95% confidence interval, 0.09 to 0.45). At 72 wk, teriparatide administration increased bone mineral density by 6.4, 3.0, and 2.3% at the lumbar spine, the total hip, and the femoral neck, respectively, compared with the placebo (P \u003c 0.01). Adverse events (AE) and the dropout rates by AE were more frequently experienced in the teriparatide group, but AE were generally mild and tolerable. Conclusion: Weekly sc administration of teriparatide at a dose of 56.5 μg may provide another option of anabolic treatments in patients with osteoporosis at higher fracture risk.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "The Journal of clinical endocrinology \u0026 metabolism, 97(9), pp.3097-3106; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "The Endocrine Society"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1210/jc.2011-3479", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2012 by The Endocrine Society."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "19457197", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Toshitaka"}], "nameIdentifiers": [{"nameIdentifier": "39825", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugimoto, Toshitsugu"}], "nameIdentifiers": [{"nameIdentifier": "39826", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakano, Tetsuo"}], "nameIdentifiers": [{"nameIdentifier": "39827", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishimoto, Hideaki"}], "nameIdentifiers": [{"nameIdentifier": "39828", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Masako"}], "nameIdentifiers": [{"nameIdentifier": "39829", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukunaga, Masao"}], "nameIdentifiers": [{"nameIdentifier": "39830", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hagino, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "39831", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sone, Teruki"}], "nameIdentifiers": [{"nameIdentifier": "39832", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "39833", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa, Yoshiki"}], "nameIdentifiers": [{"nameIdentifier": "39834", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujita, Takuo"}], "nameIdentifiers": [{"nameIdentifier": "39835", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiraki, Masataka"}], "nameIdentifiers": [{"nameIdentifier": "39836", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JCEM97_3097.pdf", "filesize": [{"value": "319.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 319600.0, "url": {"label": "JCEM97_3097.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/9845/files/JCEM97_3097.pdf"}, "version_id": "f6a6c0d3-44be-4080-b6c6-add1628405b5"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "abdominal discomfort", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aged", "subitem_subject_scheme": "Other"}, {"subitem_subject": "article", "subitem_subject_scheme": "Other"}, {"subitem_subject": "backache", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bone density", "subitem_subject_scheme": "Other"}, {"subitem_subject": "constipation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "contact dermatitis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "controlled study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "contusion", "subitem_subject_scheme": "Other"}, {"subitem_subject": "diarrhea", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dizziness", "subitem_subject_scheme": "Other"}, {"subitem_subject": "double blind procedure", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug efficacy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug response", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug safety", "subitem_subject_scheme": "Other"}, {"subitem_subject": "drug withdrawal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "eczema", "subitem_subject_scheme": "Other"}, {"subitem_subject": "female", "subitem_subject_scheme": "Other"}, {"subitem_subject": "fragility fracture", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gallbladder cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gastritis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "headache", "subitem_subject_scheme": "Other"}, {"subitem_subject": "heart disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hypercalcemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Japan", "subitem_subject_scheme": "Other"}, {"subitem_subject": "major clinical study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "malaise", "subitem_subject_scheme": "Other"}, {"subitem_subject": "male", "subitem_subject_scheme": "Other"}, {"subitem_subject": "multicenter study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nausea", "subitem_subject_scheme": "Other"}, {"subitem_subject": "osteoarthritis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "phase 3 clinical trial", "subitem_subject_scheme": "Other"}, {"subitem_subject": "primary osteoporosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "priority journal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "randomized controlled trial", "subitem_subject_scheme": "Other"}, {"subitem_subject": "rhinopharyngitis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "risk factor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "risk reduction", "subitem_subject_scheme": "Other"}, {"subitem_subject": "treatment outcome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "upper respiratory tract infection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ureter stone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "vertebra fracture", "subitem_subject_scheme": "Other"}, {"subitem_subject": "vomiting", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/30518", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-09-02"}, "publish_date": "2013-09-02", "publish_status": "0", "recid": "9845", "relation": {}, "relation_version_is_last": true, "title": ["Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk"], "weko_shared_id": -1}
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
http://hdl.handle.net/10069/30518
http://hdl.handle.net/10069/30518aa1a3ca0-b268-4776-b113-665a807f43dd
名前 / ファイル | ライセンス | アクション |
---|---|---|
JCEM97_3097.pdf (319.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-09-02 | |||||
タイトル | ||||||
タイトル | Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | abdominal discomfort | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | aged | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | article | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | backache | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | bone density | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | constipation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | contact dermatitis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | controlled study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | contusion | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | diarrhea | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | dizziness | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | double blind procedure | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug efficacy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug response | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug safety | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | drug withdrawal | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | eczema | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | female | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | fragility fracture | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gallbladder cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gastritis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | headache | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | heart disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hypercalcemia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Japan | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | major clinical study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | malaise | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | male | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | multicenter study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | nausea | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | osteoarthritis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | phase 3 clinical trial | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | primary osteoporosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | priority journal | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | randomized controlled trial | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | rhinopharyngitis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | risk factor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | risk reduction | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | treatment outcome | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | upper respiratory tract infection | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ureter stone | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | vertebra fracture | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | vomiting | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Nakamura, Toshitaka
× Nakamura, Toshitaka× Sugimoto, Toshitsugu× Nakano, Tetsuo× Kishimoto, Hideaki× Ito, Masako× Fukunaga, Masao× Hagino, Hiroshi× Sone, Teruki× Yoshikawa, Hideki× Nishizawa, Yoshiki× Fujita, Takuo× Shiraki, Masataka |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Context: Weekly teriparatide injection at a dose of 56.5 μg has been shown to increase bone mineral density. Objective: A phase 3 study was conducted to determine the efficacy of once-weekly teriparatide injection for reducing the incidence of vertebral fractures in patients with osteoporosis. Design and Setting: In this randomized, multicenter, double-blind, placebo-controlled trial conducted in Japan, the incidence of morphological vertebral fractures by radiographs was assessed. Patients: Subjects were 578 Japanese patients between the ages of 65 and 95 yr who had prevalent vertebral fracture. Intervention: Subjects were randomly assigned to receive once-weekly sc injections of teriparatide (56.5 μg) or placebo for 72 wk. Main Outcome Measure: The primary endpoint was the incidence of new vertebral fracture. Results: Once-weekly injections of teriparatide reduced the risk of new vertebral fracture with a cumulative incidence of 3.1% in the teriparatide group, compared with 14.5% in the placebo group (P < 0.01), and a relative risk of 0.20 (95% confidence interval, 0.09 to 0.45). At 72 wk, teriparatide administration increased bone mineral density by 6.4, 3.0, and 2.3% at the lumbar spine, the total hip, and the femoral neck, respectively, compared with the placebo (P < 0.01). Adverse events (AE) and the dropout rates by AE were more frequently experienced in the teriparatide group, but AE were generally mild and tolerable. Conclusion: Weekly sc administration of teriparatide at a dose of 56.5 μg may provide another option of anabolic treatments in patients with osteoporosis at higher fracture risk. | |||||
書誌情報 |
The Journal of clinical endocrinology & metabolism 巻 97, 号 9, p. 3097-3106, 発行日 2012-09-01 |
|||||
出版者 | ||||||
出版者 | The Endocrine Society | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 19457197 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1210/jc.2011-3479 | |||||
権利 | ||||||
権利情報 | © 2012 by The Endocrine Society. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | The Journal of clinical endocrinology & metabolism, 97(9), pp.3097-3106; 2012 |